ProMIS Neurosciences Inc is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company also plans to investigate additional synucleionapathies, including Parkinson's disease, and dementia with Lewy bodies. It operates in Canada.
相关临床试验
2
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
50.0%
已完成
1
50.0%
暂无批准数据
- ProMIS Neurosciences reported strong interim safety and biomarker signals for PMN310, a differentiated antibody targeting toxic amyloid-beta oligomers, in a phase I-B Alzheimer's study. - Top-line results from the phase I-B trial are expected in the first quarter of 2027, according to the company's conference presentation. - The company said it is well-funded, is advancing a robust pipeline, and is planning for phase III development and commercial expansion.
- ProMIS Neurosciences published peer-reviewed research demonstrating that plasma phosphorylated tau (pTau) biomarkers can predict clinical outcomes in Alzheimer's disease trials with strong correlation (≈0.78). - The analysis showed plasma pTau changes at 6 months were 2.6 times larger than clinical effects at 12 months, enabling smaller trials with approximately 100 participants for proof-of-concept studies. - The findings validate ProMIS's biomarker-driven approach in their ongoing PRECISE-AD Phase 1b trial of PMN310, with interim results expected in Q2 2026. - PMN310 received FDA Fast Track designation and is designed to selectively target toxic amyloid-beta oligomers while avoiding plaque binding to reduce ARIA risk.
- ProMIS Neurosciences received FDA Fast Track designation for PMN310, a therapeutic candidate targeting Alzheimer's disease, driving stock prices up 177% in pre-market trading. - The company's PMN310 is currently in Phase 1b trials evaluating safety, tolerability, and pharmacokinetics in early Alzheimer's patients, with interim results expected in Q2 2026. - Wall Street analysts maintain a Moderate Buy rating with an average price target of $3.50, representing potential 695% upside from current levels. - Trading volume surged to over 79 million shares compared to the three-month daily average of 3.5 million shares following the FDA announcement.
- The global Multiple System Atrophy (MSA) market is experiencing significant growth driven by emerging alpha-synuclein targeting therapies and advanced diagnostic technologies including high-resolution MRI and biomarker identification. - Over 20 companies are developing 22+ MSA treatment therapies across various clinical phases, with recent FDA Fast Track designations granted to ATH434 by Alterity Therapeutics and amlenetug by H. Lundbeck A/S. - Despite promising pipeline developments, the MSA market faces challenges including absence of curative therapies, diagnostic complexity due to symptom overlap with Parkinson's disease, and limited commercial incentives due to the rare patient population. - Leading pharmaceutical companies including Biohaven Pharmaceuticals, Merck & Co., AstraZeneca, and emerging biotech firms are focusing on disease-modifying treatments targeting alpha-synuclein aggregation pathways.
- ProMIS Neurosciences will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025. - CEO Neil Warma will represent ProMIS, discussing the company's focus on antibody therapeutics for neurodegenerative diseases. - A live webcast of the fireside chat will be available on the company's website for at least 30 days following the event. - ProMIS is advancing PMN310, a monoclonal antibody targeting toxic Aβ oligomers in Alzheimer's disease, currently in Phase 1b trials.
- ProMIS Neurosciences has begun a Phase 1b clinical trial (PRECISE-AD) to evaluate PMN310 for Alzheimer's, targeting toxic amyloid-beta oligomers. - The trial will assess PMN310's safety, tolerability, and pharmacokinetics over 12 months in 100 patients with mild cognitive impairment or early Alzheimer's. - PMN310 is engineered to selectively target toxic amyloid-beta oligomers, potentially reducing the risk of ARIA, a common side effect of existing therapies. - Interim data from the PRECISE-AD trial, being conducted across 22 sites in the US, is anticipated in the first half of 2026.
- PMN310, a monoclonal antibody targeting toxic amyloid beta oligomers, was well-tolerated in a Phase 1a trial with healthy volunteers. - The trial demonstrated that PMN310 crosses the blood-brain barrier, reaching cerebrospinal fluid concentrations suitable for target engagement. - ProMIS Neurosciences plans to initiate a Phase 1b clinical trial in Alzheimer's disease patients by the end of 2024, based on these results. - The Phase 1a data supports monthly dosing of PMN310 to maintain effective drug levels in the central nervous system.
- ProMIS Neurosciences presented Phase 1a clinical trial data for PMN310, indicating it was generally well-tolerated in healthy volunteers. - The study showed PMN310 crossed the blood-brain barrier, with pharmacokinetics suggesting monthly dosing could achieve target engagement in Alzheimer's patients. - A Phase 1b clinical trial in Alzheimer's disease patients with mild cognitive impairment is planned to commence by the end of 2024. - PMN310 is designed to selectively target soluble amyloid beta oligomers, believed to be a primary driver of Alzheimer's disease pathology.
